HCmed is proud to announce that our Pulmogine Vibrating Mesh Nebulizer has been approved by the U.S. Food and Drug Administration (FDA) for use with Pulmozyme, a widely prescribed medication for cystic fibrosis patients.

Pulmogine is now one of only five FDA-approved mesh nebulizer devices that can be utilized with Pulmozyme, a critical therapeutic option for individuals living with cystic fibrosis. This landmark approval underscores our unwavering commitment to developing innovative, high-quality medical technologies that enhance patient care and outcomes.

The Pulmogine Vibrating Mesh Nebulizer is designed to deliver medication effectively, with a focus on efficient drug delivery, ease of use, and patient satisfaction. This latest FDA approval further strengthens our position as a trusted partner in the respiratory care industry.

At HCmed, we are committed to driving innovation and improving the lives of patients through our cutting-edge medical technologies. We are excited to see the positive impact that the Pulmogine Vibrating Mesh Nebulizer will have on cystic fibrosis patients and their families.